Nucleot(s)ide analogues and peginterferon (PEG-IFN) treatment are the only approved
therapies for
chronic hepatitis B virus (HBV)
infection. However, complete eradication of the virus, as indicated by persistent loss of
hepatitis B surface antigen (
HBsAg), is rare among treated patients. This is due to long-term persistence of the HBV genome in infected hepatocytes in the form of covalently closed
circular DNA (cccDNA). In this study, we investigated whether administration of a large dose of a
nucleoside analogue in combination with PEG-IFN can achieve long-term loss of
HBsAg in human hepatocyte chimeric mice. Mice were treated with a high dose of
entecavir and/or PEG-IFN for 6 weeks. High-dose combination
therapy with both drugs resulted in persistently negative HBV
DNA in serum. Although small amounts of HBV
DNA and cccDNA (0.1 and 0.01 copy/cell, respectively) remained in the mouse livers, some of the mice remained persistently negative for serum HBV
DNA at 13 weeks after cessation of the
therapy. Serum
HBsAg and
hepatitis B core-related
antigen (HBcrAg) continued to decrease and eventually became negative at 12 weeks after cessation of the
therapy. Analysis of the HBV genome in treated mice showed accumulation of G-to-A hypermutation and CpG III island methylation. Persistent loss of serum HBV
DNA and loss of HBV markers by high-dose
entecavir and PEG-IFN combination treatment in chimeric mice suggests that control of HBV can be achieved even in the absence of a cellular immune response.